6 results about "Bendamustine" patented technology

Provided herein are pharmaceutical formulations of dry-powder bendamustine suitable for pharmaceutical use. Also provided are methods of producing dry-powder bendamustine. The pharmaceutical formulations can be used for any disease that is sensitive to treatment with bendamustine, such as neoplastic diseases.

Treatment methods using bendamustine formulations designed for intravenous administration of small volumes are described. These methods allow for faster administration without precipitation of the active ingredient, compared to currently available formulations.

A pharmaceutical composition comprising: (a) bendamustine; (b) sulfobutyl ether beta-cyclodextrin ("SBECD"); (c) optionally, sodium chloride; and (d) aqueous diluent; characterized in that the SBECD concentration is between 40% and 60% (w / w) based upon the combined weight of the SBECD and aqueous diluent. In addition, a kit comprising (a) a vial of such liquid pharmaceutical composition and (b) a stabilizing agent; as well as a method of treating a cancer patient comprising administering to such patient an effective dose of such pharmaceutical composition.

(3R, 4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H- chromen-7-ol (TRX-E-002-1) for use in a method of treatment for a hematological cancer being acute myeloid leukemia or multiple myeloma in a subject in need thereof, the method comprising administering to the subject an effective amount of TRX-E-002-1. The method may further comprise administering to the subject an effective amount of a second compound selected from the group consisting of (i) a BCL-2 inhibitor such as venetoclax, navitoclax or obatoclax, (ii) a deoxycytidine analogue chemotherapeutic such as cytarabine or gemcitabine, (iii) a hypomethylating agent such as azacitidine or decitabine, (iv) an anthracycline chemotherapeutic such as daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin or mitoxantrone, (v) a proteasome inhibitor such as carfilzomib, bortezomib, and ixazomib, (vi) an immunomodulatory drug such as pomalidomide, lenalidomide, and thalidomide and(vii) a corticosteroid drug such as dexamethasone or prednisone, and (viii) an alkylator such as bendamustine, cyclophosphamide, melphalan, and melflufen. Corresponding combination pharmaceutical compositions.

A pharmaceutical composition comprising: (a) bendamustine; (b) sulfobutyl ether beta-cyclodextrin (“SBECD”); (c) optionally, sodium chloride; and (d) aqueous diluent; characterized in that the SBECD concentration is between 40% and 60% (w / w) based upon the combined weight of the SBECD and aqueous diluent. In addition, a kit comprising (a) a vial of such liquid pharmaceutical composition and (b) a stabilizing agent; as well as a method of treating a cancer patient comprising administering to such patient an effective dose of such pharmaceutical composition.